RNZ Discusses mRNA Vaccine Technology
Researchers observed that if virus-killing levels were above a certain threshold, individuals did not become infected. A bridging study can use data from a 4,000-person study to demonstrate good antibody responses. When a new flu strain emerges, the RNA printer's code can be changed to match the circulating strain, allowing for a smaller clinical study.
Topics
Developing
- 907d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 907d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 907d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 907d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
RNZ National
“So what we can do is something called a bridging study where we can say, we'll take the data from this 4,000 people study and learn that we can make those good antibody responses. And then when the new flu strain emerges, we change the cassette, the code, the thing in the RNA printer, much more similar to the one that's circulating. You can do a much smaller clinical study.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade